CASP4 and non-small cell lung carcinoma: The survival rate of NSCLC patients at stage I who presented higher levels (> 377 pg/ml) of tissue-associated caspase-4 was lower (median = 0.967 years) than patients at stage I who presented lower (< 377 pg/ml) levels (median = 3.02 years) (Fig. 1f).